High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Drug resistance in Plasmodium parasites is a constant threat. Novel therapeutics, especially new drug combinations, must be identified at a faster rate. In response to the urgent need for new antimalarial drug combinations we screened a large collection of approved and investigational drugs, tested 13,910 drug pairs and identified many promising antimalarial drug combinations. The activity of known antimalarial drug regimens was confirmed and a myriad of new classes of positively interacting drug pairings were discovered. Network and clustering analyses reinforced established mechanistic relationships for known drug combinations and identified several novel mechanistic hypotheses. From eleven screens comprising >4,600 combinations per parasite strain (including duplicates) we further investigated interactions between approved antimalarials, calcium homeostasis modulators and inhibitors of phosphatidylinositide 3-kinases (PI3K) and the mammalian target of rapamycin (mTOR). These studies highlight important targets and pathways and provide promising leads for clinically actionable antimalarial therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Nzila, A. M., Mberu, E. K., Sulo, J., Dayo, H., Winstanley, P. A., Sibley, C. H., & Watkins, W. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.991-996.2000 · Cited by 232
Cited by
SynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T., & Tang, J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 530
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 436
Wooten, D. J., Meyer, C. T., Lubbock, A. L. R., Quaranta, V., & Lopez, C. F. (2021) · Nature Communications · doi:10.1038/s41467-021-24789-z · Cited by 97
A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth
Lal-Nag, M., McGee, L., Guha, R., Lengyel, E., Kenny, H. A., & Ferrer, M. (2017) · SLAS Discovery · doi:10.1177/2472555216687082 · Cited by 33
Self-citationSnider, D., & Weathers, P. J. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113638 · Cited by 23
“Although the mechanism of action for both artemisinin and MB are not fully elucidated, it is thought that MB is an oxidative stress inducer that specifically targets the cellular antioxidant protein glutathione reductase (Delves et al., 2013; Mott et al., 2015).”
Background
Metadata
- Authors
- Mott, B. T., Eastman, R. T., Guha, R., Sherlach, K. S., Siriwardana, A., Shinn, P., McKnight, C., Michael, S., Lacerda-Queiroz, N., Patel, P. R., Khine, P., Sun, H., Kasbekar, M., Aghdam, N., Fontaine, S. D., Liu, D., Mierzwa, T., Mathews-Griner, L. A., Ferrer, M., Renslo, A. R., Inglese, J., Yuan, J., Roepe, P. D., Su, X.-Z., & Thomas, C. J.
- Venue
- Scientific Reports
- Published
- 2015-09-25
- Volume
- 5
- Issue
- 1
- Pages
- 13891-13891
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2217028767
- Cited by
- 103
- References
- 5
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.